Sinorda Pharmaceutical Named to the "2025 China's Top 101 Innovative Pharmaceutical Companies" List

From August 1 to 2, 2025, the 7th CMC-CHINA China Pharmaceutical Industry Expo (PharmExpo) was held at the Suzhou International Expo Center. During the event, the "2025 China Pharmaceutical Industry TOP101" and the list of 10 core industry chains were unveiled, with Sinorda Pharma named among the "2025 China Innovative Pharmaceutical Companies TOP101."

As a biopharmaceutical innovation company in the commercialization phase, Sinorda Pharma has consistently focused on the research and development—and subsequent industrialization—of innovative drugs targeting gastrointestinal diseases, tumor immunotherapy, and autoimmune disorders. Since its establishment, the company has remained committed to its original mission: delivering superior treatment options to patients, and continues to forge ahead with relentless exploration on the path of drug discovery and development.

The "2025 China's Top 101 Innovative Pharmaceutical Companies" list was jointly launched by PharmaCircle, a platform specializing in precise connections between pharmaceutical information and industry networks, and CMC-CHINA, the China Pharmaceutical Industry Expo. The selection process involved a comprehensive evaluation based on multiple dimensions, including market capitalization, business performance, R&D pipelines, commercialization strategies, R&D investment, as well as incubation and business development activities. This initiative aims to carefully identify the most innovative and promising pharmaceutical companies, providing an objective snapshot of China's leading players in the innovative drug sector. Sinorda Pharma’s recognition underscores the company’s prominent position in the field of innovative drugs, highlighting its strong leadership and significant growth potential.

In the future, Sinorda Pharma will continue to uphold the innovation-driven development philosophy, relentlessly deepening its efforts in the research, development, and commercialization of groundbreaking drugs for gastrointestinal diseases, tumor immunotherapy, and autoimmune disorders—contributing significantly to elevating China’s innovative drug R&D capabilities and safeguarding the health and well-being of the people.